Case ponders pharma's web shyness in keynote

Share this article:
Case: industry is under-invested in web
Case: industry is under-invested in web

Steve Case, chairman and CEO of Revolution Health and co-founder of AOL, yesterday lamented pharma's hesitation to embrace interactive and inject a greater share of promotional budget into online initiatives.

“It is astonishing to me how under-invested this industry is in digital media,” Case told delegates at the 7th annual ePharma Summit in Philadelphia. “This is crazy.”

The biggest problem, he said, is that consumers are not actively engaged, referring to how easy it is to log onto the web on a Sunday afternoon to buy, say, U2 concert tickets, but how it is not possible to schedule an appointment with a doctor.

However, Case is confident that, given time, present hurdles to online initiatives, such as regulatory and privacy issues, will be overcome and that the healthcare community will start to “experiment more aggressively” and eventually embrace digital media. He recalled the early days of e-commerce as an example of how online attitudes and user behavior transform over time.

“If I'd stood up back then and suggested that consumers would enter their credit card number onto [Amazon.com], that the number would be stored for future purchases, and that the site would recommend what they should buy next time, I'd have been run out of the room.”

Case, whose mission is to turn Revolution Health into the largest online healthcare network, urged the 300 or so marketers in attendance to stick with it, reminding them that this is a fun business to be in.

“Although the second 10 years [at Time Warner] was where all the fame and fortune was,” he revealed, “I actually enjoyed the first 10 years more—and I was better at it.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...